YB-200, a novel IgG1 antibody targeting CEACAM1/5, induces complete response in syngeneic liver Hepa1-6 tumor-bearing mice and modulates the immune response
Download full poster below.
CIMT 2023 poster
Download PDF • 680KB
RIEHEN, SWITZERLAND, April 26, 2023 ─ Ymmunobio, a preclinical stage biotech company specializing in the development of innovative treatments for cancer patients, has been selected to present findings from its lead asset YB-200 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) on May 4, 2023.
Ymmunobio CEO Dr. Katrin Rupalla said, “It’s an honor to participate in Europe’s largest meeting focused on cancer immunotherapy research and development. We look forward to sharing results from our research into the mechanism of action of our monoclonal antibody YB-200. This is a great opportunity to discuss our science and answer any questions.”
TITLE: "YB-200, a novel IgG1 antibody targeting CEACAM1/5, induces complete response in syngeneic liver Hepa1-6 tumor-bearing mice and modulates the immune response"
POSTER NUMBER: #197
FIRST AUTHOR: Michel Janicot, PhD, CDO, Ymmunobio
TIME: Thursday, 4 May 2023 between 3:30 pm - 6:00 pm.
CIMT invites international participants for high-level scientific exchange, collaboration, and education focused on cancer immunotherapy.
This year’s plenary speakers at CIMT represent the leading scientists and researchers from around the world and include Lisa Meier McShane, PhD, Associate Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute, U.S. National Institutes of Health; Marcela Maus, MD, Associate Professor at Harvard Medical School, the Paula O’Keefe Chair in Oncology and Director of Cellular Immunotherapy at Massachusetts General Hospital (MGH) Cancer Center; Stefan Fröhling, MD, Head of the Division of Translational Medical Oncology at the German Cancer Research Center; Anne Rios, MD, group leader and head of the imaging center of the Princess Maxima Center for Pediatric Oncology, Ultrecht, Netherlands; and Rob Manguso, PhD, Assistant Professor of Medicine in the Massachusetts General Hospital Cancer Center and Harvard Medical School and an Associate Member in the Cancer Program at the Broad Institute of MIT and Harvard.
Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments focus on high unmet need indications in gastro-intestinal cancers. Learn more on Ymmunobio’s website and follow on LinkedIn.
Investor Relations: Dr. Katrin Rupalla, firstname.lastname@example.org